A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
Phase 1/2
Terminated
NCT05979831
| Condition | Netherton Syndrome |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Daiichi Sankyo |
|---|
| Status | Terminated |
|---|
| Enrollment | 9 participants |
|---|
| Interventions | DS-2325a |
|---|
| Start date | Sep 28, 2023 |
|---|
| Completion date | Jan 6, 2025 |
|---|
| Results posted | May 14, 2026 |
|---|
Summary
Netherton Syndrome (NS) is a severe rare disease characterized by generalized scaling, erythema, and epidermal barrier defects. This study assessed the safety, pharmacokinetics (PK), and efficacy of DS-2325a in patients with NS.
Number of Participants With Treatment-emergent Adverse Events
Screening (Day 0) up to Week 45 (end of study) · Participants
| DS-2325a (Observational Part) | 2 Participants |
|---|
| Placebo (Observational Part) | 2 Participants |
|---|
| DS-2325a (Interventional Part Main Phase) | 5 Participants |
|---|
| Placebo (Interventional Part Main Phase) | 4 Participants |
|---|
| DS-2325a (Interventional Part Extension Phase) | 4 Participants |
|---|
| Placebo (Interventional Part Extension Phase) | 2 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.